Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

R. Brahmer, Julie; Abu‐Sbeih, Hamzah; A. Ascierto, Paolo; Brufsky, Jill; C. Cappelli, Laura; B. Cortazar, Frank; E. Gerber, David; Hamad, Lamya; Hansen, Eric; B. Johnson, Douglas; E. Lacouture, Mario; A. Masters, Gregory; Naidoo, Jarushka; Nanni, Michele; Perales, Miguel‐Angel; Puzanov, Igor; Santomasso, Bianca; Shanbhag, Satish; Sharma, Rajeev; Skondra, Dimitra; A. Sosman, Jeffrey; Turner, Michelle; S. Ernstoff, Marc

doi:10.1136/jitc-2021-002435

Public

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

Published in Journal for ImmunoTherapy of Cancer • Jun 1, 2021

Authors:

Julie R. Brahmer

Hamzah Abu‐Sbeih

Paolo A. Ascierto

Abstract

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers. While these immunotherapies have improved patient outcomes in many clinical settings, they bring accompanying risks of toxicity, specifically immune-related adverse events (irAEs). There is a need for ...

Subject

Medicine

Guideline

Adverse effect

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!